RLMD
NASDAQRelmada Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$5.71-0.33 (-5.54%)
01:30 PM07:30 PM
News · 26 weeks39-71%
2025-12-142026-06-07
Mix2090d
- SEC Filings12(60%)
- Earnings4(20%)
- Other3(15%)
- Analyst1(5%)
Latest news
25 items- SECRelmada Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- PRRelmada Therapeutics to Present at the Jefferies Global Healthcare ConferenceCORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026. Jefferies Global Healthcare Conference DetailsFormat: Fireside ChatDate: Thursday, June 4, 2026Time: 12:50 PM ETWebcast: Click Here Management will also be available for one-on-one investor meetings during the conference. Please co
- SECSEC Form S-3ASR filed by Relmada Therapeutics Inc.S-3ASR - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Relmada Therapeutics Inc.SCHEDULE 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
- SECRelmada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- SECSEC Form 10-Q filed by Relmada Therapeutics Inc.10-Q - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- PRRelmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatePositive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBCOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Filed provisional patent application with the USPTO in April 2026 covering NDV-01 pharmaceutical formulations and methods of treatment; if issued, patents claiming priority to the provisional filing would ha
- PRRelmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress. Conference Call and Webcast Information: Date: Tuesday, May 12, 2026 at 4:30 PM ETParticipant Dial-in (US): 1-800-717-1738Participant Dial-in (International): 1-646-307-1865Webcast Access: Click Here A replay of the webcast will be available in the
- PRRelmada Therapeutics to Present NDV-01 Abstracts at AUA202612-Month Phase 2 data in High-Risk NMIBC to be presented Friday, May 15, 2026Phase 3 overview to be presented at Trials-in-Progress session on Sunday, May 17, 2026The Phase 3 "RESCUE" registrational program remains on track to be initiated mid-2026 CORAL GABLES, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the presentation of two abstracts related to NDV-01 at the American Urology Association (AUA2026), taking place from May 15-18th in Washington D.C. Abstract Overview* Abstract #1: Post
- SECSEC Form DEFA14A filed by Relmada Therapeutics Inc.DEFA14A - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- SECSEC Form DEF 14A filed by Relmada Therapeutics Inc.DEF 14A - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- SECSEC Form EFFECT filed by Relmada Therapeutics Inc.EFFECT - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- SECSEC Form 424B3 filed by Relmada Therapeutics Inc.424B3 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- SECSEC Form PRE 14A filed by Relmada Therapeutics Inc.PRE 14A - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- SECSEC Form S-3 filed by Relmada Therapeutics Inc.S-3 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- ANALYSTPiper Sandler initiated coverage on Relmada Therapeutics with a new price targetPiper Sandler initiated coverage of Relmada Therapeutics with a rating of Overweight and set a new price target of $12.00
- SECRelmada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- SECSEC Form 10-K filed by Relmada Therapeutics Inc.10-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- PRRelmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business UpdatePositive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profileCompleted an oversubscribed $160 million PIPE financing led by leading healthcare investors in March 2026, strengthens balance sheet to support NDV-01 Phase 3 developmentOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Cash balance of $93.0 million as of December 31, 2025, plus gross proceeds of $160 million from March 2026 PIPE expected to fund operations through 2029, including comple
- PRRelmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss financial results for the fourth quarter ended December 31, 2025, and recent business progress. Conference Call and Webcast Information: Date: Thursday, March 19, 2026 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Webcast Access: Click Here A replay of the webcast will be avai
- PRRelmada Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceCORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Leerink Partners Global Healthcare Conference being held in Miami, Florida, from March 8-11, 2026. Leerink Partners Global Healthcare Conference DetailsFormat: Fireside ChatDate Tuesday, March 10, 2026Time: 8:40 AM ETWebcast: Click Here Management will also be available for one-one-one investor meetings during the c
- SECRelmada Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
- PRRelmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement FinancingCORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $160.0 million to the Company, before placement agent fees and offering expenses. The PIPE financing included participation from Venrock Healthcare Capital Partners, Commodore Capital, Janus Henderson Investors, RA Capital Management, Balyasny Asset Man
- PRRelmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder CancerDurable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerability profile remains favorable – no ≥ Grade 3 treatment-related adverse events and no treatment-related discontinuations Data reinforces advancement of NDV-01 into Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology a
- PRPsychedelic Medicine Advances: Here Are Five Companies Targeting CNS DisordersIssued on behalf of Helus PharmaVANCOUVER, BC, Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week, signaling a potential shift in how regulators and investors view psychedelic-based psychiatry[1]. The pathway is widening at the federal level, where the Drug Enforcement Administration raised its 2026 psilocybin production quota by 67%[2]. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), Relmada Therapeutics (NASDAQ:RLMD), Alto Neuroscience (NYSE:ANRO), and Axsome
RLMD FAQ
6 questionsWhat does Relmada Therapeutics Inc. do?
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan...Where does RLMD stock trade?
Relmada Therapeutics Inc. (RLMD) is listed on NASDAQ.What sector and industry is RLMD in?
Relmada Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about RLMD?
Relmada Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $1200.00 price target on 2026-03-24.What companies are similar to RLMD?
Notable peers in the same industry include VTGN (Vistagen Therapeutics Inc.), CTXR (Citius Pharmaceuticals Inc.), ATXI (Avenue Therapeutics Inc.). Compare RLMD side-by-side with any of them on Quantisnow.How can I track RLMD on Quantisnow?
Quantisnow aggregates Relmada Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RLMD to receive live email and push alerts on every new disclosure.